醋酸阿比特龙-话题@MedSci

#醋酸阿比特龙#

17篇内容 | 895人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1368440, encodeId=98221368440eb, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Int J Clin Oncol：前期接受醋酸阿比特龙和多西他赛治疗的转移性去势敏感前列腺癌患者的真实结果和风险分层 , objectType=article, longId=730534, objectId=206be305347e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=206be305347e, replyNumber=0, likeNumber=44, createdTime=2022-06-28, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=206be305347e, moduleTitle=Int J Clin Oncol：前期接受醋酸阿比特龙和多西他赛治疗的转移性去势敏感前列腺癌患者的真实结果和风险分层 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=206be305347e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368439, encodeId=1786136843925, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Eur J Cancer：醋酸阿比特龙联合强尼松(AA+P)治疗转移性去势敏感前列腺癌(mCSPC)伴有内脏转移(VM)患者的疗效, objectType=article, longId=293794, objectId=b06d293e94c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b06d293e94c3, replyNumber=0, likeNumber=0, createdTime=2022-01-12, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b06d293e94c3, moduleTitle=Eur J Cancer：醋酸阿比特龙联合强尼松(AA+P)治疗转移性去势敏感前列腺癌(mCSPC)伴有内脏转移(VM)患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b06d293e94c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368438, encodeId=31d9136843835, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=J Clin Oncol：醋酸阿比特龙在去势抵抗、雄激素受体表达的唾液腺癌(SGC)患者中的疗效, objectType=article, longId=218068, objectId=1d31218068f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d31218068f3, replyNumber=0, likeNumber=33, createdTime=2021-10-04, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d31218068f3, moduleTitle=J Clin Oncol：醋酸阿比特龙在去势抵抗、雄激素受体表达的唾液腺癌(SGC)患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d31218068f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368437, encodeId=f5fc136843e0d, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Eur J Cancer：耄耋之年mCRPC患者采用恩杂鲁胺治疗的效果优于醋酸阿比特龙, objectType=article, longId=212999, objectId=791f2129998e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=791f2129998e, replyNumber=0, likeNumber=48, createdTime=2021-06-22, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=791f2129998e, moduleTitle=Eur J Cancer：耄耋之年mCRPC患者采用恩杂鲁胺治疗的效果优于醋酸阿比特龙, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=791f2129998e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368436, encodeId=fce113684363c, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Clin Cancer Res：醋酸阿比特龙通过诱导CREB1磷酸化和增强CBP-p300复合物的功能导致前列腺癌细胞产生耐药 , objectType=article, longId=207004, objectId=fbdc20e00493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbdc20e00493, replyNumber=0, likeNumber=46, createdTime=2021-02-11, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbdc20e00493, moduleTitle=Clin Cancer Res：醋酸阿比特龙通过诱导CREB1磷酸化和增强CBP-p300复合物的功能导致前列腺癌细胞产生耐药 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbdc20e00493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368435, encodeId=b60f136843592, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Prostate Cancer P D：恩扎鲁胺和醋酸阿比特龙相关的骨靶向治疗和骨骼相关事件 , objectType=article, longId=200970, objectId=ca5c2009e0a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca5c2009e0a8, replyNumber=0, likeNumber=42, createdTime=2020-09-22, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca5c2009e0a8, moduleTitle=Prostate Cancer P D：恩扎鲁胺和醋酸阿比特龙相关的骨靶向治疗和骨骼相关事件 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca5c2009e0a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368434, encodeId=3ffd1368434d4, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Clin Cancer Res：阿帕鲁胺联合醋酸阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌！, objectType=article, longId=198652, objectId=f4a019865234, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4a019865234, replyNumber=0, likeNumber=44, createdTime=2020-08-05, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4a019865234, moduleTitle=Clin Cancer Res：阿帕鲁胺联合醋酸阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4a019865234)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368433, encodeId=26f813684332a, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Lancet Oncol：醋酸阿比特龙+恩杂鲁胺治疗转移性去势抵抗性前列腺癌的更佳顺序, objectType=article, longId=183078, objectId=978d1830e88d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=978d1830e88d, replyNumber=0, likeNumber=34, createdTime=2019-11-17, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=978d1830e88d, moduleTitle=Lancet Oncol：醋酸阿比特龙+恩杂鲁胺治疗转移性去势抵抗性前列腺癌的更佳顺序, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=978d1830e88d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368432, encodeId=f2631368432f0, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Eur Urol：醋酸阿比特龙加强的松或恩杂鲁胺治疗对转移去势难治性前列腺癌患者报道结果的影响研究, objectType=article, longId=182264, objectId=060e182264cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=060e182264cd, replyNumber=0, likeNumber=31, createdTime=2019-11-04, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=060e182264cd, moduleTitle=Eur Urol：醋酸阿比特龙加强的松或恩杂鲁胺治疗对转移去势难治性前列腺癌患者报道结果的影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=060e182264cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368431, encodeId=4a7c1368431a4, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Prostate Cancer P D：去势敏感性前列腺癌中醋酸阿比特龙与多烯紫杉醇治疗成本效益分析, objectType=article, longId=175788, objectId=811c1e5788de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=811c1e5788de, replyNumber=0, likeNumber=36, createdTime=2019-07-21, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=811c1e5788de, moduleTitle=Prostate Cancer P D：去势敏感性前列腺癌中醋酸阿比特龙与多烯紫杉醇治疗成本效益分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=811c1e5788de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368430, encodeId=eaaa136843055, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期, objectType=article, longId=164282, objectId=b041164282af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b041164282af, replyNumber=0, likeNumber=40, createdTime=2019-04-16, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b041164282af, moduleTitle=Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b041164282af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368429, encodeId=2d2f1368429e4, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Lancet oncol：醋酸阿比特龙联合镭-223不能延长去势耐受性前列腺癌骨转移患者的无症状骨骼事件存活期, objectType=article, longId=159655, objectId=7e6a15965554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e6a15965554, replyNumber=0, likeNumber=53, createdTime=2019-02-10, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e6a15965554, moduleTitle=Lancet oncol：醋酸阿比特龙联合镭-223不能延长去势耐受性前列腺癌骨转移患者的无症状骨骼事件存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e6a15965554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368428, encodeId=4bc6136842864, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Clin Cancer Res：醋酸阿比特龙治疗的前列腺癌患者中游离DNA修饰动态研究, objectType=article, longId=135019, objectId=0aac135019d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0aac135019d0, replyNumber=0, likeNumber=47, createdTime=2018-04-13, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0aac135019d0, moduleTitle=Clin Cancer Res：醋酸阿比特龙治疗的前列腺癌患者中游离DNA修饰动态研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0aac135019d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368427, encodeId=6f9b136842eba, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Eur Urol：比较醋酸阿比特龙和多西他赛联合雄激素剥夺治疗在高风险和转移性未经激素治疗的前列腺癌中的作用：系统评价与荟萃分析。, objectType=article, longId=116259, objectId=4d8911625997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8911625997, replyNumber=0, likeNumber=32, createdTime=2017-10-17, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8911625997, moduleTitle=Eur Urol：比较醋酸阿比特龙和多西他赛联合雄激素剥夺治疗在高风险和转移性未经激素治疗的前列腺癌中的作用：系统评价与荟萃分析。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8911625997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368426, encodeId=f79b1368426b8, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Eur Urol：醋酸阿比特龙联合泼尼松治疗未接受化疗的转移性去势抵抗性前列腺癌的分层分析。, objectType=article, longId=114003, objectId=36ba114003d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36ba114003d2, replyNumber=0, likeNumber=41, createdTime=2017-09-26, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36ba114003d2, moduleTitle=Eur Urol：醋酸阿比特龙联合泼尼松治疗未接受化疗的转移性去势抵抗性前列腺癌的分层分析。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36ba114003d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368425, encodeId=34811368425f2, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=Clin Cancer Res：醋酸阿比特龙加强的松对前列腺癌疫苗的作用, objectType=article, longId=50198, objectId=6e43501987b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e43501987b, replyNumber=0, likeNumber=38, createdTime=2015-05-06, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e43501987b, moduleTitle=Clin Cancer Res：醋酸阿比特龙加强的松对前列腺癌疫苗的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e43501987b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368424, encodeId=98ed1368424ca, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, objectTitle=European Urology ：醋酸阿比特龙治疗去势抵抗性前列腺癌, objectType=article, longId=47514, objectId=1cab4e514e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cab4e514e4, replyNumber=0, likeNumber=38, createdTime=2015-02-25, rootId=0, userName=zexyw01, userId=362b271, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cab4e514e4, moduleTitle=European Urology ：醋酸阿比特龙治疗去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cab4e514e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

醋酸阿比特龙

2020-05-29

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Int J Clin Oncol：前期接受醋酸阿比特龙和多西他赛治疗的转移性去势敏感前列腺癌患者的真实结果和风险分层

2022-06-28

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Eur J Cancer：醋酸阿比特龙联合强尼松(AA+P)治疗转移性去势敏感前列腺癌(mCSPC)伴有内脏转移(VM)患者的疗效

2022-01-12

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

J Clin Oncol：醋酸阿比特龙在去势抵抗、雄激素受体表达的唾液腺癌(SGC)患者中的疗效

2021-10-04

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Eur J Cancer：耄耋之年mCRPC患者采用恩杂鲁胺治疗的效果优于醋酸阿比特龙

2021-06-22

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Clin Cancer Res：醋酸阿比特龙通过诱导CREB1磷酸化和增强CBP-p300复合物的功能导致前列腺癌细胞产生耐药

2021-02-11

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Prostate Cancer P D：恩扎鲁胺和醋酸阿比特龙相关的骨靶向治疗和骨骼相关事件

2020-09-22

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Clin Cancer Res：阿帕鲁胺联合醋酸阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌！

2020-08-05

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Lancet Oncol：醋酸阿比特龙+恩杂鲁胺治疗转移性去势抵抗性前列腺癌的更佳顺序

2019-11-17

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Eur Urol：醋酸阿比特龙加强的松或恩杂鲁胺治疗对转移去势难治性前列腺癌患者报道结果的影响研究

2019-11-04

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Prostate Cancer P D：去势敏感性前列腺癌中醋酸阿比特龙与多烯紫杉醇治疗成本效益分析

2019-07-21

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Lancet oncol：ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期

2019-04-16

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Lancet oncol：醋酸阿比特龙联合镭-223不能延长去势耐受性前列腺癌骨转移患者的无症状骨骼事件存活期

2019-02-10

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Clin Cancer Res：醋酸阿比特龙治疗的前列腺癌患者中游离DNA修饰动态研究

2018-04-13

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Eur Urol：比较醋酸阿比特龙和多西他赛联合雄激素剥夺治疗在高风险和转移性未经激素治疗的前列腺癌中的作用：系统评价与荟萃分析。

2017-10-17

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Eur Urol：醋酸阿比特龙联合泼尼松治疗未接受化疗的转移性去势抵抗性前列腺癌的分层分析。

2017-09-26

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

Clin Cancer Res：醋酸阿比特龙加强的松对前列腺癌疫苗的作用

2015-05-06

zexyw01 (审核中...)

前往app查看评论内容

#醋酸阿比特龙#

European Urology ：醋酸阿比特龙治疗去势抵抗性前列腺癌

2015-02-25

科室
- - 订阅+
  - 更多科室
工具
服务